STRATA Skin Science Announces Strengthening of Leadership Team
December 04 2023 - 8:00AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical
technology company dedicated to developing, commercializing and
marketing innovative products for the treatment of dermatologic
conditions, today announced the promotion of Shmuel Gov to Chief
Operating Officer. The Company has also hired Dr. Amandeep Kaur as
Vice President of Marketing and Business Growth.
“I am pleased to announce the promotion of
Shmuel to Chief Operating Officer. His outstanding leadership,
strategic insight, and continued commitment to our mission make him
the ideal choice to drive our operational excellence. This
appointment reflects our confidence in Shmuel’s ability to elevate
our organization. I look forward to his continued impact and
working more closely with him again as we revamp our
direct-to-consumer activities, and services to our customers,
allowing me to focus on the sales, marketing, business development
and the aspects of managing the overall Company,” commented Dr.
Dolev Rafaeli, Vice Chairman and Chief Executive Officer.
Shmuel Gov brings over 30 years of industry
experience in medical device business, operations, and R&D
and, most recently, was STRATA’s
Senior Vice President and General Manager in charge of operations
at the Company’s manufacturing and R&D facility in Carlsbad,
CA. Prior to joining the Company as Vice President and General
Manager, he managed the acquisition of LasikPlus for Photomedex
(from whom STRATA acquired its core XTRAC® and VTRAC® product
lines), in which he was instrumental in building the unique
go-to-market strategy of providing value-added services to the
XTRAC partners. In 2015, he transitioned to STRATA after STRATA
acquired XTRAC and has led the technological updates and the
R&D of the XTRAC product line, including the launch of S3® and
Momentum®. He has also created an in-house call center and enhanced
the reimbursement support functions. Mr. Gov holds degrees in
electronics engineering and international business management.
“I am truly honored to take on the pivotal role
of Chief Operating Officer. This promotion not only acknowledges my
individual contributions but also reflects the unwavering
dedication of our exceptional team. I look forward to leading and
contributing to STRATA’s growth, promoting operational excellence,
and tackling the challenges ahead. Together, we will reach new
heights and achieve success in our shared journey,” expressed
Shmuel Gov, Chief Operating Officer of STRATA.
Additionally, Dr. Amandeep Kaur has rejoined
STRATA and brings years of experience and background in business
development, marketing, and technology. In her previous tenure at
STRATA, Dr. Kaur was instrumental in business development efforts,
led the XTRAC at-home initiative, managed multiple clinical studies
and their publications, and worked closely with the clinical,
marketing, and sales teams on multiple marketing and sales
initiatives. Dr. Kaur earned her Master of Business Administration
from Cornell University Johnson School of Business.
Dr. Rafaeli commented further, “It is a pleasure
to have Dr. Kaur rejoin our team, and we look forward to her
contributions as we revitalize our sales and marketing efforts to
align with our new business objectives. Aman brings subject matter
knowledge and a specific understanding of how the unique STRATA
go-to-market approach of providing value-added services helps grow
the recurring sales model. Her close ties with the clinical and
research community and her experience as a business development
leader will help STRATA accomplish its near-term turn-around
goals.”
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical
technology company dedicated to developing, commercializing and
marketing innovative products for the in-office treatment of
various dermatologic conditions such as psoriasis, vitiligo, and
acne. Its products include the XTRAC® excimer laser,
VTRAC® lamp systems, and the TheraClear®X Acne Therapy
System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership
Program. STRATA’s popular partnership approach includes a fee per
treatment cost structure versus an equipment purchase, installation
and use of the device, on-site training for practice personnel,
service and maintenance of the equipment, dedicated account and
customer service associates, and co-op advertising support to help
raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995. These statements include but are not limited to the
Company’s plans, objectives, expectations and intentions and may
contain words such as “will,” “may,” “seeks,” and “expects,” that
suggest future events or trends. These statements, the Company’s
ability to launch and sell an acne treatment device and to
integrate that device into its product offerings, the Company’s
ability to develop, launch and sell products recently acquired or
to be developed in the future, the Company’s ability to develop
social media marketing campaigns, direct to dermatologist marketing
campaigns, and the Company’s ability to build a leading franchise
in dermatology and aesthetics, are based on the Company’s current
expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may
differ materially from the Company’s expectations due to financial,
economic, business, competitive, market, regulatory, adverse market
conditions labor supply shortages, or supply chain interruptions
resulting from the coronavirus, fiscal, and political factors,
responses, or conditions affecting the Company, the medical device
industry and our customers and patients in general, as well as more
specific risks and uncertainties set forth in the
Company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all these forward-looking
statements may prove to be incorrect or unreliable. The statements
in this press release are made as of the date of this press
release, even if subsequently made available by the Company on its
website or otherwise. The Company does not undertake any obligation
to update or revise these statements to reflect events or
circumstances occurring after the date of this press release. The
Company urges investors to carefully review
its SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.Investor
Contact:Rich CockrellCG CapitalPhone: +1 (404)
736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024